UBS downgraded Arcellx (ACLX) to Neutral from Buy with a price target of $115, up from $110, citing Gilead’s (GILD) acquisition of Arcellx for of $7.8B or $115 per share. The acquisition makes sense, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX: